These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 24826990)
1. Loss of central auditory processing in a mouse model of Canavan disease. von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990 [TBL] [Abstract][Full Text] [Related]
3. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190 [TBL] [Abstract][Full Text] [Related]
4. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
5. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013 [TBL] [Abstract][Full Text] [Related]
6. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262 [TBL] [Abstract][Full Text] [Related]
7. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375 [TBL] [Abstract][Full Text] [Related]
8. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model. Becker I; Wang-Eckhardt L; Eckhardt M J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891 [TBL] [Abstract][Full Text] [Related]
9. Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism. Lotun A; Li D; Xu H; Su Q; Tuncer S; Sanmiguel J; Mooney M; Baer CE; Ulbrich R; Eyles SJ; Strittmatter L; Hayward LJ; Gessler DJ; Gao G Prog Neurobiol; 2023 Jul; 226():102460. PubMed ID: 37149081 [TBL] [Abstract][Full Text] [Related]
10. Redirecting Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442 [TBL] [Abstract][Full Text] [Related]
11. Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease. Takeda S; Hoshiai R; Tanaka M; Izawa T; Yamate J; Kuramoto T; Kuwamura M Exp Anim; 2024 Jul; 73(3):347-356. PubMed ID: 38538326 [TBL] [Abstract][Full Text] [Related]
12. The pathogenesis of, and pharmacological treatment for, Canavan disease. Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725 [TBL] [Abstract][Full Text] [Related]
13. rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System. Ahmed SS; Schattgen SA; Frakes AE; Sikoglu EM; Su Q; Li J; Hampton TG; Denninger AR; Kirschner DA; Kaspar B; Matalon R; Gao G Mol Ther; 2016 Jun; 24(6):1030-1041. PubMed ID: 27039844 [TBL] [Abstract][Full Text] [Related]
14. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy. Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719 [TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900 [TBL] [Abstract][Full Text] [Related]
16. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model. Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021 [TBL] [Abstract][Full Text] [Related]
17. A new mouse model of Canavan leukodystrophy displays hearing impairment due to central nervous system dysmyelination. Carpinelli MR; Voss AK; Manning MG; Perera AA; Cooray AA; Kile BT; Burt RA Dis Model Mech; 2014 Jun; 7(6):649-57. PubMed ID: 24682784 [TBL] [Abstract][Full Text] [Related]
18. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination. Mattan NS; Ghiani CA; Lloyd M; Matalon R; Bok D; Casaccia P; de Vellis J Neurobiol Dis; 2010 Nov; 40(2):432-43. PubMed ID: 20637282 [TBL] [Abstract][Full Text] [Related]
19. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model. Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859 [TBL] [Abstract][Full Text] [Related]
20. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]